Testing for a coronavirus vaccine in Australia is set to begin next week, with more than 100 people volunteering for trials.
Australian clinical trials specialist Nucleus Network is partnering with US-based biotechnology company Novavax aiming to begin Phase One testing of the NVX-CoV2373 vaccine in the coming days.
This clinical trial will be the first of its kind in the Southern Hemisphere, with 131 people in Brisbane and Melbourne set to be injected with a potential vaccine.
Scientists will now choose subjects for testing from the pool of healthy people who have volunteered.
“Nucleus has a rich history of Phase 1 vaccine trials, and a long-standing track-record with Novavax; we are well positioned to implement rapid testing with first-in-human trials over the coming weeks,” Nucleus CEO Cameron Johnson said.
“With the capacity to conduct this trial across both our Melbourne and Brisbane clinics, we will be assisting Novavax to undertake Phase One trials and fast track NVX-CoV2373 to potential subsequent development as soon as possible.”
Novavax has previously been responsible for early development efforts on vaccines for SARS and Middle East respiratory syndrome (MERS), two other coronavirus epidemics.
“The urgent global race to develop a vaccine against the COVID-19 pandemic drove our rapid identification and selection of an optimal, highly immunogenic vaccine candidate,” Novavax CEO Stanley Erck said.
Preliminary results are expected by July.
For breaking news alerts and livestreams straight to your smartphone sign up to the 9News app and set notifications to on at the App Store or Google Play.